Clinical trials: Oral Chemotherapy
Gastroesophageal Reflux Disease, Erosive Esophagitis
Safety and Efficacy of Dexlansoprazole Delayed-Release Capsules for Healing of Erosive Esophagitis and Maintenance of Healed Erosive Esophagitis and Relief of Heartburn in Adolescents
The purpose of this study is to assess the safety and effectiveness of treatment with once daily oral administration of dexlansoprazole delayed-release capsules in adolescents with erosive esophagitis (EE) and for maintenance of…
- Trial name
- NCT01642615
- Testing
- Dexlansoprazole
- Where
- 60 sites in United States, Belgium and 6 more
- Volunteers
- 63 people
- Sponsor
- Takeda
Renal Cell Cancer, Prostate Cancer
Improving Outcomes in Cancer Patients on Oral Anti-Cancer Medications Using a Multi-modal Mobile Health Intervention
This study evaluates a smart phone based mobile application designed for patients with Renal Cell and Prostate Cancer taking oral anti-cancer medications.
- Conditions
- Renal Cell Cancer, Prostate Cancer, Effects of Chemotherapy
- Trial name
- CORA (NCT02375776)
- Testing
- CORA- Device:smartphones"
- Where
- United States
- Volunteers
- 84 people
- Sponsor
- Massachusetts General Hospital
Acute Myeloid Leukemia (AML)
A Study of Oral Venetoclax Tablets and Oral Azacitidine as Maintenance Therapy in Adult Participants With Acute Myeloid Leukemia in First Remission After Conventional Chemotherapy
This study will be conducted in two parts. Part 1 will be the Dose Confirmation portion to determine recommended Phase 3 dose (RPTD) of venetoclax in combination with azacitidine (AZA).
- Trial name
- VIALE-M (NCT04102020)
- Testing
- Venetoclax, Azacitidine
- Where
- 156 sites in United States, Australia and 17 more
- Volunteers
- 112 people
- Sponsor
- AbbVie
Head and Neck Cancer
Combination Chemotherapy Plus Radiation Therapy in Treating Patients With Advanced Head and Neck Cancer
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Radiation therapy uses high-energy x-rays to damage tumor cells.
- Trial name
- NCT00003888
- Testing
- cisplatin, docetaxel, fluorouracil
- Where
- 44 sites in Austria, Belgium and 13 more
- Volunteers
- 359 people
- Sponsor
- European Organisation for Research and Treatment of Cancer - EORTC
Oral Mucositis in Head and Neck Cancer, Chemo-radiotherapy
A Study on the Effectiveness of Olive Oil Mouthwash in Alleviating Chemoradiotherapy-induced Oral Mucositis in Patients With Head and Neck Cancer.
Backgroud: Radiation therapy and concurrent chemoradiotherapy are the main treatment methods for patients with head and neck cancer, which often lead to many severe oral mucositis (OM).
- Trial name
- NCT07293013
- Testing
- olive oil mouthwash
- Where
- Taiwan
- Volunteers
- 120 people
- Sponsor
- Chiayi Christian Hospital
Leukemia
Combination Chemotherapy in Treating Children With Newly Diagnosed Acute Lymphoblastic Leukemia
RATIONALE: Drugs used in chemotherapy use different ways to stop cancer cells from dividing so they stop growing or die. Combining more than one drug and giving them in different ways may kill more cancer cells.
- Trial name
- NCT00002744
- Testing
- asparaginase, cyclophosphamide, cytarabine
- Where
- 34 sites in United States, Australia and 1 more
- Volunteers
- 1,970 people
- Sponsor
- Children's Oncology Group
HIV Infections
A Study of Dextran Sulfate in HIV-Infected Patients and in Patients With AIDS or AIDS Related Complex (ARC)
To determine the effectiveness and safety of dextran sulfate (DS) as a treatment for patients with AIDS, AIDS related complex (ARC), or asymptomatic HIV infection with or without persistent generalized lymphadenopathy (PGL), and…
- Trial name
- NCT00001009
- Testing
- Dextran sulfate
- Where
- 8 sites in United States
- Volunteers
- 60 people
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
Breast Cancer, Chronic Myeloproliferative Disorders
Motexafin Gadolinium and Doxorubicin in Treating Patients With Advanced Cancer
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Motexafin gadolinium may increase the effectiveness of doxorubicin by making tumor cells more sensitive to…
- Conditions
- Breast Cancer, Chronic Myeloproliferative Disorders, Colorectal Cancer, Head and Neck Cancer
- Trial name
- NCT00036790
- Testing
- doxorubicin hydrochloride, motexafin gadolinium
- Where
- 2 sites in United States
- Sponsor
- University of Wisconsin, Madison
Prostate Cancer
A Phase 2 Study to Evaluate the Safety and Efficacy of TAK-385, Together With a Leuprorelin Observational Cohort, in Participants With Prostate Cancer
The purpose of this study is to evaluate the efficacy of TAK 385 for achieving and maintaining testosterone suppression (<50 ng/dL).
- Trial name
- NCT02083185
- Testing
- Relugolix, Leuprorelin
- Where
- 23 sites in United States, Canada
- Volunteers
- 136 people
- Sponsor
- Millennium Pharmaceuticals, Inc.
Cancer
Randomized Discontinuation Study of Lapatinib Versus Placebo in Subjects With Documented Tumor Progression After Chemotherapy, or Where no Approved Therapy Exists
This study will examine the efficacy and safety of lapatinib in patients with ErbB2 positive ovarian, gastric/esophageal adenocarcinoma, uterine serous papillary, or bladder cancers.
- Trial name
- NCT00447226
- Where
- 20 sites in United States
- Volunteers
- 32 people
- Sponsor
- GlaxoSmithKline
Head and Neck Cancer
Surgery, Radiation Therapy, and Combination Chemotherapy in Treating Patients With Recurrent Head and Neck Cancer
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Radiation therapy uses high-energy x-rays to damage tumor cells.
- Trial name
- NCT00003777
- Testing
- amifostine trihydrate, cisplatin, fluorouracil
- Where
- United States
- Volunteers
- 35 people
- Sponsor
- Abramson Cancer Center at Penn Medicine
Brain and Central Nervous System Tumors
Thalidomide, Celecoxib, and Combination Chemotherapy in Treating Patients With Relapsed or Refractory Malignant Glioma
RATIONALE: Thalidomide and celecoxib may stop the growth of tumor cells by stopping blood flow to the tumor. Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die.
- Trial name
- NCT00047281
- Testing
- celecoxib, cyclophosphamide, etoposide
- Where
- 3 sites in United States
- Sponsor
- Dana-Farber Cancer Institute
Gastroesophageal Reflux Disease (GERD)
A Study to Check the Safety of Dexlansoprazole and Learn if it Can Treat Symptomatic Nonerosive Gastroesophageal Reflux Disease in Children 2 to 11 Years Old
Gastroesophageal reflux disease (GERD) is caused by food or acid coming up from the stomach into the esophagus, repeatedly. The esophagus is the tube that carries food and liquids from the mouth to the stomach.
- Trial name
- NCT02616302
- Testing
- Dexlansoprazole
- Where
- 18 sites in United States, Canada and 3 more
- Volunteers
- 71 people
- Sponsor
- Takeda
AML, Acute Myelogenous Leukemia
Diagnosis and Treatment of Periodontal Disease in Patients With AML
This is a phase 2 randomized controlled trial of pre-chemotherapy periodontal deep cleaning in Acute Myelogenous Leukemia (AML) patients with asymptomatic periodontitis.
- Trial name
- NCT04530695
- Testing
- Scaling and Root Planing
- Sponsor
- Masonic Cancer Center, University of Minnesota
Advanced Solid Neoplasms, Lymphoma Neoplasms
A Study to Assess Mass Balance, Pharmacokinetics (PK), and Metabolism of Orally Administered [14 C]-TAK-659 in Participants With Advanced Solid Tumor and/or Lymphoma Malignancies
The purpose of this study is to assess the mass balance and to characterize the pharmacokinetics (PK) in plasma and urine, and of total radioactivity in plasma and whole blood following a single oral dose of [14C]-TAK-659…
- Trial name
- NCT03338881
- Testing
- [14C]-TAK-659, TAK-659
- Sponsor
- Calithera Biosciences, Inc
Nausea and Vomiting, Chemotherapy-Induced
A Study of the Drug Casopitant for the Prevention of Nausea Caused By Cisplatin-Based Highly Emetogenic Chemotherapy
This is a Phase III trial designed to demonstrate that casopitant when added to dexamethasone and ondansetron is more effective in the prevention of vomiting then dexamethasone and ondansetron alone, in patients who receive a…
- Trial name
- NCT00431236
- Testing
- Oral Casopitant (GW679769), IV Casopitant (GW679769), IV ondansetron hydrochloride
- Where
- 80 sites in Argentina, Belgium and 20 more
- Volunteers
- 810 people
- Sponsor
- GlaxoSmithKline
Metastatic Renal Cell Carcinoma
Impact of the PRISM-care Multidisciplinary Oncology Program on Secured Drug Intake of Patients With Kidney Cancer
The rise of oral targeted therapies favors outpatient care of cancer patients but exposes them to new risks compared to the injectable chemotherapy in the hospital: non-adherence to treatment, inappropriate management of side…
- Trial name
- PRISM care (NCT02849535)
- Testing
- PRISM care program
- Where
- 12 sites in France
- Volunteers
- 190 people
- Sponsor
- Hospices Civils de Lyon
Nausea and Vomiting, Chemotherapy-Induced
Study Of Healthy Subjects To Assess The Effect Of Ketoconazole And The Way The Body Will React To Casopitant [GW679769]
This is a two period study of healthy adult subjects to characterize the effect of the dosing of ketoconazole on the the way the body reacts to a dose of GW679769, and to assess the safety profile of oral casopitant with and…
- Trial name
- NCT00404378
- Testing
- ketoconazole, casopitant 100 mg, Casopitant 50 mg
- Where
- United States
- Volunteers
- 15 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
Metastatic Breast Cancer
Evaluate the Meritup Oral Solution to Decrease Fatigue in Metastatic Breast Cancer Patients Receiving Chemotherapy
A randomized, double-blind, placebo-controlled, parallel study to evaluate the safety profile and ability of Meritup oral solution to decrease fatigue in metastatic breast cancer patients receiving chemotherapy.
- Trial name
- NCT06151249
- Testing
- Meritup oral solution
- Volunteers
- 32 people
- Sponsor
- Chung Shan Medical University
Allergic Rhinitis
Allergic Rhinitis Combination Pharmacotherapy Efficacy Study
Combination pharmacotherapy is often used in people who have failed mono-therapies in managing their bothersome allergic rhinitis symptoms .
- Trial name
- NCT04601324
- Testing
- Fluticasone Propionate, Azelastine hydrochloride and fluticasone propionate, Rupatadine
- Volunteers
- healthy volunteers welcome
- Sponsor
- St. Paul's Sinus Centre